Application of ACSL4 in diagnosis and treatment of depression

By discovering the key role of ACSL4 in depression, using ACSL4 as a target to develop diagnostic and therapeutic supplies, we solved the problems of lack of objective indicators in the diagnosis and treatment of depression and poor drug effect, and achieved effective diagnosis and treatment of depression and treat.

CN118932041APending Publication Date: 2024-11-12CHONGQING MEDICAL UNIVERSITY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410991234.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-23
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

There is a lack of objective indicators in the early diagnosis and treatment of depression, resulting in high misdiagnosis and misdiagnosis rates, poor results of existing treatment drugs and adverse reactions, and lack of new therapeutic targets.

Method used

By discovering the key role of ACSL4 in depression, using ACSL4 as a target, by detecting ACSL4 protein and interfering with its gene expression, ACSL4 inhibitors and diagnostic kits are developed for the diagnosis and treatment of depression.

Benefits of technology

New objective biomarkers and therapeutic targets are provided, which can improve depression symptoms and neuronal function, reduce depression susceptibility, and alleviate depression symptoms.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118932041A_ABST
    Figure CN118932041A_ABST
Patent Text Reader

Abstract

The invention discloses application of ACSL4 in diagnosis and treatment of depression, and discovers that the expression level of ACSL4 in blood plasma of a patient with depression is remarkably increased, and the expression level of ACSL4 in blood plasma and hippocampal brain tissue of a depression-sensitive mouse is further remarkably increased. Therefore, the ACSL4 can be used for diagnosing depression. It is found that by inhibiting expression and activity of ACSL4, the depressive symptom of a depression model mouse can be obviously improved, and the form and function of neurons of the depression model mouse can be improved. On the contrary, the expression of ACSL4 is up-regulated, so that the damage of neuron morphology and function can be induced, the susceptibility of depression is increased, and the occurrence of depression is induced. The experiments show that ACSL4 is a potential target spot for diagnosing and treating depression. By inhibiting the expression of ACSL4, for example, the expression of ACSL4 or a coding gene thereof, or inhibiting the biological activity of ACSL4, the effect of improving depression is achieved, at least the form and function of neurons can be improved, and the depression symptom can be relieved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biomedicine, and specifically to the application of ACSL4 in the diagnosis and treatment of depression. Background Art

[0002] Major depressive disorder (MDD) is a common persistent and severe mental illness in clinical practice. It is a disease caused by various reasons with low mood or mood and loss of interest as the core symptoms. According to statistics, 13% to 20% of people have experienced depression, with a lifetime prevalence of 6.1% to 28.2%. The prevalence of depression in my country is about 6.87%, and it is estimated that about 90 million people are affected. From 1990 to 2007, the number of depression cases worldwide increased by 49.86%. According to WHO statistics, about 322 million people in the world are suffering from depression. Depression has inevitably become the largest single factor causing non-fatal health loss, and it is predicted that major depression will become the number one burden disease in 2030. As a chronic disease, depression not only impairs an individual's ability to cope with normal life, but can also coexist with other chronic diseases. For example, with cardiovascular disease, diabetes and other diseases, it will aggravate the damage to normal body functions, reduce the quality of life, affect its prognosis, and increase the risk of death. Clinical studies have also found that depression is highly correlated with neurological diseases. For example, common neurological diseases such as Alzheimer's disease, Parkinson's disease, Huntington's disease and epilepsy are often accompanied by mental symptoms such as depression. Depression has brought a huge disease burden to people and has become an important public health issue.

[0003] Long-chain acyl-CoA synthetase (ACSL) is a member of the acyl-activating enzyme family and contains 5 different subtypes, each encoded by a different gene. The ACSL4 gene is located in the X chromosome, and the protein ACSL it encodes contains 5 isomers, namely ACSL1, 3, 4, 5, and 6. They can convert free long-chain fatty acids into fatty acyl-CoA for the synthesis of cellular lipids and the promotion of β-oxidation degradation. ACSL4 is abundant in the adrenal glands, ovaries, testes, and brain tissues, and is mainly distributed in the endoplasmic reticulum, mitochondria, and peroxisomes. The ACSLs family not only affects lipid metabolism in the body, but also plays an important role in cell proliferation and apoptosis. Disorders in the function of ACSL4 can lead to many diseases related to it, such as liver disease, diabetes, nervous system diseases, and malignant tumors. Dixon et al., the discoverer of ferroptosis, found that ACSL4 may play an important role in ferroptosis.

[0004] Ferroptosis is a new type of cell death discovered in recent years. Different from traditional programmed cell death, ferroptosis is characterized by morphological changes such as iron ion accumulation, reactive oxygen accumulation, mitochondrial shrinkage and increased membrane density, and can mediate cell death through multiple pathways.

[0005] Early diagnosis and timely treatment of depression are very important. To date, the diagnosis of depression still mainly relies on the evaluation of symptomology and psychological scales, such as the Hamilton Depression Rating Scale (HAMD), the Self-Rating Depression Scale (SDS), and the Patient Health Questionnaire Depression Scale (PHQ-9) to assist in the diagnosis of depression. However, clinical symptoms are often a subjective feeling, and psychological scales, whether self-rating or peer-rating, are also subjective and lack objective indicators as support. It is precisely because of the lack of objective biological diagnostic indicators that the current missed diagnosis and misdiagnosis rates of depression are high, delaying the treatment opportunity. Therefore, research on the pathogenesis of depression and improving the level of diagnosis and treatment have become major issues that need to be urgently addressed in today's depression research. Although attempts have been made to explore objective diagnostic indicators from endocrine, inflammation, metabolism, genomics, neuroimaging, etc., there is no conclusion yet. Therefore, it is very necessary for us to continue to explore the pathogenesis of depression and find objective biological indicators from it, so as to provide a practical and effective solution for the clinical diagnosis of depression.

[0006] The pathogenesis of depression is complex. It is now believed that it is related to genetics, neurobiology, and psychosocial and cultural factors, and multiple mechanisms are involved in the interaction. At present, although there are a large number of hypotheses, such as neurotransmitter disorders and HPA axis disorders, these theories cannot fully explain the pathogenesis of depression. Current clinical treatment drugs for depression mainly relieve clinical symptoms by increasing monoamine neurotransmitters in the brain, such as 5-hydroxytryptamine and norepinephrine reuptake inhibitors, selective 5-hydroxytryptamine reuptake inhibitors, etc. Clinical antidepressant treatment is mainly based on drugs, but the unsatisfactory effects, significant treatment lags, and intolerable adverse reactions of the drugs currently used reflect the huge clinical demand for new antidepressant drugs. Therefore, it is necessary to continue to explore new pathogenesis of depression and find new therapeutic targets.

[0007] In summary, there is an urgent need in this field to develop new targets that can be used for the diagnosis and treatment of depressive disorders. Summary of the invention

[0008] The present invention found that in the animal model of depression, iron content or ferroptosis-related genes showed significant changes, which means that abnormal iron metabolism in the brain may be a potential factor in the pathophysiological changes of depression. The present invention's research found that targeting ACSL4 has a diagnostic effect on depression; targeting ACSL4, knocking down the ACSL4 gene can improve the related symptoms of depression and has a therapeutic effect on depression; overexpressing the ACSL4 gene can increase the susceptibility to depression and has an inductive effect on depression.

[0009] The purpose of the present invention is to provide new targets and strategies for the diagnosis and treatment of depression. Depression can be diagnosed by detecting ACSL4 protein, and depression can be treated by intervening in ACSL4 gene.

[0010] The present invention implements the detection of the expression level of ACSL4 in peripheral plasma by ELISA on the serum of depression patients and healthy control group. The results show that compared with the healthy control group, the expression level of ACSL4 in the plasma of depression patients is significantly increased. Through further experiments, it is found that inhibiting the expression and activity of ACSL4 can significantly improve the depressive symptoms of depression model mice and improve the morphology and function of neurons in depression model mice. On the contrary, upregulating the expression of ACSL4 can increase the susceptibility to depression, induce depression, and induce damage to the morphology and function of neurons. Through the above experiments, it is shown that ACSL4 is a potential target for the diagnosis and treatment of depression. By inhibiting ACSL4, for example, inhibiting the expression of ACSL4 or its encoding gene, or inhibiting the biological activity of ACSL4, it has an improvement effect on the treatment of depression, at least it can improve the morphology and function of neurons and alleviate depressive symptoms.

[0011] In view of this, the present invention proposes the use of ACSL4 in the preparation of depression diagnosis and / or treatment products.

[0012] Optionally, the therapeutic product includes an ACSL4 inhibitor to inhibit the expression of ACSL4 gene or ACSL4 protein.

[0013] Preferably, the ACSL4 inhibitor improves the morphology and function of neurons.

[0014] Preferably, the ACSL4 inhibitor inhibits the transcriptional activity of the ACSL4 gene by inhibiting the activity of transcription factors, chromatin remodeling, DNA methylation, and activating or inhibiting cell signaling pathways;

[0015] Preferably, the ACSL4 inhibitor can selectively reduce ACSL4 translation through RNA splicing regulation, RNA stability regulation, RNA interference, and post-translational modification, thereby controlling the expression level of ACSL4 protein.

[0016] More preferably, the ACSL4 inhibitor is a viral vector that inhibits the expression of ACSL4.

[0017] More preferably, the viral vector is an adeno-associated viral vector.

[0018] In some embodiments of the present invention, the adeno-associated viral vector is an AAV8 viral vector.

[0019] In other embodiments, the adenovirus-associated virus vector may also be selected from AAV1, AAV2, AAV5, AAV6, AAV7 or AAV9, etc., and those skilled in the art may select a suitable type of virus vector as needed.

[0020] It should be noted that, given that ACSL4 and its gene sequence are known, those skilled in the art can easily prepare relevant viral vectors that inhibit ACSL4 gene expression using conventional techniques in the art.

[0021] In addition, those skilled in the art can also use RNA interference technology to inhibit the expression of the patient's ACSL4 gene at the transcriptional level. Therefore, the use of related products aimed at inhibiting the ACSL4 gene and suitable for RNA interference technology as drugs for treating depression also falls within the scope of protection of the present invention.

[0022] Optionally, in some embodiments of the present invention, the drug is in the form of an injection.

[0023] Those skilled in the art can use suitable dosage forms of the above-mentioned inhibitors to treat depression as needed, including but not limited to injections. No matter which dosage form is used, it does not require creative work by those skilled in the art. Therefore, the use of any dosage form of the above-mentioned inhibitors to treat depression falls within the scope of protection of the present invention.

[0024] In another aspect, the diagnostic supplies include a kit for detecting ACSL4 gene or protein.

[0025] The present invention also provides the use of ACSL4 gene or ACSL4 protein as a target for diagnosis and / or treatment of depression.

[0026] The present invention also provides the use of ACSL4 gene or ACSL4 protein as a drug target for preparing drugs for treating depression.

[0027] The present invention reveals the key role of ACSL4 in depression, provides a new theory and strategy for the research and treatment of depression, and lays a foundation for the development of new target molecules related to the treatment of depression.

[0028] Based on the contents disclosed in the present invention, those skilled in the art can also use gene therapy technology, such as using a suitable viral vector to introduce into the patient's body to achieve the treatment of depression. As long as the viral vector can inhibit the expression of ACSL4, such as inhibiting its gene expression to reduce the level of ACSL4, the treatment effect of depression can be achieved.

[0029] Based on the research results of the embodiments of the present invention, it is easy for those skilled in the art to think of using ACSL4 as a target or target to treat depression, and the corresponding drugs are easily obtained or screened by those skilled in the art based on the research results of the present invention. These drugs can inhibit the activity of ACSL4, causing it to lose its normal biological function; they can also inhibit the expression of the ACSL4 gene, such as inhibiting transcription or inhibiting translation, etc. These drugs all use ACSL4 as a target to treat depression, and they all belong to the protection scope of the present invention.

[0030] The present invention has the following beneficial technical effects:

[0031] 1. The present invention provides new objective biomarkers for the diagnosis of depression;

[0032] 2. The present invention provides a new target for the treatment of depression;

[0033] 3. The present invention provides a new target for exploring the mechanism of depression. BRIEF DESCRIPTION OF THE DRAWINGS

[0034] In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the drawings required for use in the embodiments are briefly introduced below. It should be understood that the following drawings only show certain embodiments of the present invention and therefore should not be regarded as limiting the scope. For ordinary technicians in this field, other related drawings can be obtained based on these drawings without creative work.

[0035] Figure 1 is the expression level of ACSL4 in the plasma of patients with depression;

[0036] In the figure:

[0037] A: ELISA detected an increased expression level of ACSL4 in peripheral plasma of patients with depression;

[0038] B: ROC curve drawn by ACSL4. ***p<0.001 represents comparison with the control group.

[0039] Figure 2 The changes of ACSL4 and ferroptosis in depressed mice;

[0040] In the figure:

[0041] A: CSDS depression mouse model;

[0042] BF: Assessment of behavioral tests reflecting depression: social interaction, sugar water preference, open field test, tail suspension test, and forced swimming;

[0043] G: ELISA detected the increased expression level of ACSL4 in the plasma of depression-sensitive mice;

[0044] H: ELISA detected the increased expression level of ACSL4 in the hippocampal brain tissue of depression-sensitive mice;

[0045] IJ: WB evaluation of ferroptosis-related regulatory factor protein levels;

[0046] K: RT-qPCR evaluation of mRNA levels of ferroptosis-related regulatory factors.

[0047] Figure 3 Knocking down ACSL4 in the hippocampus can exert an antidepressant effect;

[0048] A: Schematic diagram of the experimental scheme;

[0049] B: Schematic diagram of knockdown virus infection, the scale bar is 500um;

[0050] CH: Assessment of behavioral tests reflecting depression: social interaction, body weight, sugar water preference test, open field test, tail suspension test and forced swim test;

[0051] *p<0.05, **p<0.01, ***p<0.001 compared with the AAV-ShAcsl4+CON group, #p<0.05, ##p<0.01, ###p<0.001 compared with the AAV-GFP+CSDS group.

[0052] Figure 4 To show the changes of neuronal damage in the hippocampus induced by chronic stress after knockdown of ACSL4 in the hippocampus;

[0053] AB: Nissl staining and statistical analysis of CA1 and DG regions of the hippocampus, scale bar is 10 μm;

[0054] C: Transmission electron microscopy evaluates the ultrastructural changes of neurons in the hippocampus. The red arrows represent mitochondria, and the scale is 2 μm.

[0055] D: WB was used to evaluate the changes in the expression of synapse-related proteins.

[0056] *p<0.05, **p<0.01, ***p<0.001 compared with the AAV-ShAcsl4+CON group, #p<0.05, ##p<0.01, ###p<0.001 compared with the AAV-GFP+CSDS group.

[0057] Figure 5 Overexpression of ACSL4 in the hippocampus can increase susceptibility to depression;

[0058] A: Schematic diagram of the experimental scheme;

[0059] B: Schematic diagram of overexpression virus infection, the scale is 500um,

[0060] CH: Assessment of behavioral tests reflecting depression: social interaction, body weight, sugar water preference test, open field test, tail suspension test and forced swim test;

[0061] *p<0.05, **p<0.01, ***p<0.001 compared with the AAV-GL3050+CON group, #p<0.05, ##p<0.01, ###p<0.001 compared with the AAV-ACSL4-SSDS group. DETAILED DESCRIPTION

[0062] In order to make the purpose, technical scheme and advantages of the embodiments of the present invention clearer, the technical scheme in the embodiments of the present invention will be described clearly and completely below. If the specific conditions are not specified in the embodiments, they are carried out according to conventional conditions or conditions recommended by the manufacturer. If the manufacturer of the reagents or instruments used is not specified, they are all conventional products that can be purchased commercially.

[0063] The features and performance of the present invention are further described in detail below in conjunction with the embodiments.

[0064] 1. The expression level of ACSL4 in the plasma of patients with depression is significantly increased

[0065] Blood samples were collected from patients with depression and healthy controls, and the expression level of ACSL4 in peripheral plasma was detected by ELISA. The results showed that the expression level of ACSL4 in plasma of patients with depression was significantly increased compared with that of the healthy control group (p<0.001, Figure 1 A); Using ACSL4 to draw the ROC curve for patients with depression, its diagnostic efficiency AUC=0.9878, p<0.001( Figure 1 B).

[0066] 2. The expression level of ACSL4 in the hippocampal brain tissue and plasma of depressed mice was significantly increased

[0067] The chronic social defeat stress (CSDS) model is a good model for simulating human depression. It is widely used in depression modeling due to its reliability and repeatability. The present invention uses a modeling step reference (A standardized protocol for repeated social defeat stress in mice) and makes certain adjustments according to actual conditions. First, CD1 mice with good aggressiveness are screened. The modeling duration of the CSDS model is 10 days. C57BL / 6J mice are placed in different cages with CD1 mice as "invaders" every day, and the stress time is about 5 minutes each time. After the modeling is completed, C57BL / 6J mice are raised in a single cage, during which they are free to eat and drink water, and behavioral tests and other experimental operations are performed.

[0068] Construction of CSDS depression mouse model ( Figure 2 A) Assessment of behavioral measures reflecting depression: social interaction, sugar water preference, open field test, tail suspension test, and forced swim ( Figure 2 BF). Depression-sensitive mice were screened using the social interaction test (SI), and the ventral hippocampal brain tissue and peripheral blood were isolated. The expression of ACSL4 in depression-sensitive mice was detected by ELISA. Compared with the control group, the expression levels of ACSL4 in plasma and hippocampal brain tissue of depression-sensitive mice were significantly increased (p<0.01) (Figure GH).

[0069] Western blot and RT-qPCR were used to evaluate the expression of ferroptosis-related regulatory factor proteins ( Figure 2 IJ) and mRNA levels ( Figure 2 K) found that the expression of NRF2 and GPX4 in the hippocampus of depression-sensitive mice was significantly downregulated, suggesting that hippocampal ferroptosis mediates the occurrence and development of depression.

[0070] 3. Adeno-associated virus-mediated shRNA interference technology was used to knock down ACSL4, confirming that it mediates the occurrence of depression

[0071] AAV viral vectors have the advantages of safety, high efficiency and low toxicity in the in vivo application of the nervous system, and are very suitable for the study of the nervous system. By injecting the AAV8-shACSL4 viral vector that can knock out the mouse ACSL4 gene into the mouse hippocampus, the expression of hippocampal ACSL4 was downregulated. After 3 weeks of viral expression, the CSDS depression model was carried out for 10 consecutive days, and the protective effect of hippocampal ACSL4 downregulation on the depression model was evaluated by behavioral tests ( Figure 3 AB). The results showed that AAV8-mediated downregulation of ACSL4 gene could alleviate the depressive symptoms of depression model mice ( Figure 3 CH).

[0072] Nissl staining was used to observe changes in neuronal morphology. The number of damaged neurons in the AAV-GFP+CSDS group increased significantly (CA1 p<0.05, DG p<0.01). After ACSL4 knockdown, neuronal damage and reduction of Nissl-positive cells in the CA1 (p<0.05) and DG (p<0.01) regions of the hippocampus of the AAV-shACSL4+CSDS group mice were improved ( Figure 4 AB). Transmission electron microscopy was used to observe the changes of neuronal mitochondria ( Figure 4 C), indicating that the mitochondria of the neurons in the AAV-GFP+CSDS group of mice were severely damaged. After ACSL4 knockdown, the degree of mitochondrial damage in the AAV-shACSL4+CSDS group was significantly reduced. Further evaluation of proteins related to synaptic function showed that postsynaptic density protein 95 (PSD95) was significantly upregulated, synaptic-associated protein (Snap25) was significantly downregulated in the AAV-shACSL4+CSDS group of mice, and synaptophysin (SYP) on the presynaptic vesicle membrane did not change significantly ( Figure 4 D), suggesting that knocking down ACSL4 can mainly improve postsynaptic and intersynaptic transmission function and plasticity. Taken together, the above results indicate that knocking down hippocampal ACSL4 can alleviate CSDS-induced neuronal damage in the hippocampus of mice.

[0073] In summary, these results suggest that injection of ACSL4 knockdown adeno-associated virus into the hippocampus can improve the depressive-like behavior and neuronal damage in mice, indicating that ACSL4 has potential antidepressant effects.

[0074] 4. Overexpression of ACSL4 based on adeno-associated virus-mediated shRNA interference technology can induce depression

[0075] It has been reported that under normal circumstances, subthreshold stimulation does not induce significant depressive-like behavior in mice. The specific operation steps of the subthreshold social frustration stress model (SSDS) are as follows: Each C57BL / 6J mouse is attacked by different CD1 mice three times in one day, each time for 10 minutes, and rests for 20 minutes after each attack.

[0076] Modeling process see Figure 5 A, AAV8-ACSL4, a viral vector that overexpresses mouse ACSL4 gene, was injected into the mouse hippocampus. Figure 5 B), ACSL4 overexpression in the hippocampus was achieved. After 3 weeks of viral expression, the overexpressed mice were subjected to subthreshold stimulation. 24 hours after the mice were subjected to subthreshold stimulation, behavioral tests were performed ( Figure 5 CH). The results showed that compared with the AAV8-ACSL4 group, the sugar preference rate of mice in the AAV8-ACSL4-SSDS group was reduced (p<0.05, Figure 5 E), the total distance moved in the open field was reduced (p<0.05, Figure 5 F), indicating that mice exhibit depressive-like behaviors. Mice overexpressing hippocampal ACSL4 exhibit depressive-like behaviors, indicating that overexpression of hippocampal ACSL4 can increase the susceptibility of mice to stress.

[0077] The above results fully demonstrate that ACSL4 can be used as a therapeutic target for depression. By administering ACSL4 inhibitors to patients with depression, depression-related symptoms of depression can be improved, as well as neuronal morphology and function. The key role of ACSL4 protein in depression provides a new theory and strategy for the research and diagnosis of depression.

[0078] The relevant detection methods involved in the above experiments are as follows:

[0079] 1. Social interaction detection (SI)

[0080] This behavior study consists of two stages. In the first stage, without the presence of CD1, mice were allowed to freely explore the open field for 2.5 minutes, and the time when C57BL / 6J mice entered the interaction zone was recorded and analyzed. In the second stage, in the presence of unfamiliar CD1, they were also allowed to freely explore for 2.5 minutes, and the time that C57BL / 6J mice participating in the first stage spent in the interaction zone was recorded. Social interaction ratio = time spent by C57BL / 6J mice in the interaction zone in the second stage / time spent by C57BL / 6J mice in the interaction zone in the first stage. If the social interaction ratio is <1, C57BL / 6J mice are classified as CSDS-sensitive mice, and if the social interaction ratio is >1, C57BL / 6J mice are classified as CSDS-resistant mice.

[0081] 2. Sucrose preference test (SPT)

[0082] Before the formal experiment, mice need to be fed with sugar water for adaptation. The experiment was conducted with pure water and 1% sugar water. After 12 hours, the consumption of sugar water and pure water was calculated respectively. Sugar water preference value = sugar water consumption / (pure water consumption + sugar water consumption) × 100%

[0083] 3. Open field test (OFT)

[0084] OFT uses a white plastic box with a size of 44cm×44cm×30cm, and the 14.7cm×14.7cm area in the center of the box is set as the central area. At the beginning of the experiment, C57BL / 6J mice were placed in the center of the open field. After 30 seconds of adaptation, the movement process of the mice was recorded for 5 minutes, and the time when the mice entered the central area within 5 minutes was analyzed.

[0085] 4. Tail suspension test (TST)

[0086] The mouse tail was attached to a hook with tape, and the mouse head was 15 cm above the ground. The test lasted for 6 minutes, and the immobility time of the mouse was analyzed in the last 4 minutes. Judgment criteria: The mouse was judged as immobile when its limbs completely stopped moving.

[0087] 5. Forced swimming test (FST)

[0088] The mice to be tested were placed in a transparent cylinder filled with 15 cm of water at a temperature of 222°C for 6 minutes, and the mice were analyzed for the immobility time after 4 minutes.

[0089] 6. Nissl staining

[0090] Specific operation: Use a paraffin slicer to cut the hippocampal brain region of C57BL / 6J mice according to the coronal section with a thickness of 4μm, pick out the cut complete brain slices, put them into Nissl staining solution, stain them at 37℃ for 5 minutes, then rinse them with 95% ethanol for 5 minutes, and after drying, rinse them in xylene twice, 5 minutes each time, and finally seal them with neutral resin and take pictures for observation.

[0091] 7. Transmission electron microscopy (TEM)

[0092] After the mice were anesthetized, PBS was first perfused. After the liver turned white, 4% paraformaldehyde was perfused, and then the hippocampal brain tissue (1 mm 3 ), placed in 2.5% glutaraldehyde and fixed overnight at 4°C. The tissue was cut along the coronal plane with a thickness of 60-80 μm.

[0093] 8. Enzyme-linked immunosorbent assay (ELISA)

[0094] (1) Preparation of tissue homogenate: Rinse the brain tissue with PBS to remove the blood remaining on the surface of the tissue; use filter paper to absorb the liquid on the surface, weigh it, and put it into an EP tube. Then add PBS at a weight-to-volume ratio of 1:9, and grind the brain tissue in a pre-cooled grinder; centrifuge the tissue homogenate at 12000rpm for 15 minutes, and take the supernatant for detection. (2) Detection: It mainly includes the steps of adding samples, adding biotinylated antibodies, washing plates, adding enzyme conjugate working solution, washing plates, adding substrates, and adding stop solution. For detailed steps, please refer to the instructions.

[0095] 9. Real-time quantitative PCR (qPCR)

[0096] 9.1 Extraction of tissue RNA

[0097] (1) Take out the sample to be tested.

[0098] (2) Add 1 ml of TRizol to the tissue, collect the grinding solution after grinding, and let it stand for 5 minutes.

[0099] (3) Add 1 / 5 volume of chloroform, place on ice for 15 minutes, and centrifuge at 12000 rpm, 4°C for 15 minutes.

[0100] (4) After centrifugation, remove the supernatant, add an equal volume of isopropanol, mix well and let stand for 10 minutes. Centrifuge at 4°C, 12,000 rpm, for 10 minutes.

[0101] (5) Keep the precipitate, add 1 ml of 75% ethanol, shake thoroughly, centrifuge at 4°C, 12,000 rpm, for 5 minutes, discard the supernatant, and keep the precipitate.

[0102] (6) Allow the precipitate to dry at room temperature for 5-10 minutes.

[0103] (7) Add an appropriate amount of DPEC water and measure the concentration and purity of RNA.

[0104] 9.2 Reverse transcription of RNA into DNA

[0105] (1) According to the instructions of the Takara kit, the genomic DNA removal reaction was performed. The system was as follows:

[0106]

[0107] After the mixture is fully mixed, react at room temperature for 5 minutes.

[0108] (2) Reverse transcription reaction system:

[0109]

[0110] The liquid in step (2) is mixed and cDNA is recovered after reverse transcription.

[0111] (3) RT-qPCR reaction

[0112]

[0113] After mixing the above reaction solution, complete the RT-qPCR reaction according to the set program. The internal reference gene is β-actin, and the expression level of the target gene is calculated using 2-△△CT.

[0114] The gene primer sequences used in the present invention are shown in Table 1 below.

[0115] Table 1 PCR primer sequences used in the present invention

[0116]

[0117] 10Western blotting (WB) experiment

[0118] 10.1 Tissue sampling and protein extraction

[0119] (1) Tissue sampling: Brain tissues from corresponding parts were collected, placed in EP tubes, and stored in a -80°C refrigerator.

[0120] (2) Weighing: Take out an appropriate volume of brain tissue, transfer it to a new EP tube, and weigh it using a balance.

[0121] (3) Lysis: Prepare protein lysis buffer. Add protein lysis buffer at a ratio of protein lysis buffer (μl): tissue weight (mg) = 10:1. Grind the tissue with a tissue grinder first, then perform ultrasonic disruption. After ultrasonication, let the tissue stand at 4°C for 30 minutes. Centrifuge in a low-temperature centrifuge for 10 minutes (12000rpm, 4°C). After centrifugation, aspirate the supernatant.

[0122] 10.2 Protein concentration determination (BCA method)

[0123] (1) Prepare a protein standard at a concentration of 0.5 mg / ml.

[0124] (2) Prepare BCA working solution at a ratio of solution A to solution B of 50:1.

[0125] (3) The standard was prepared into 8 different concentration gradients of 0, 0.025 mg / ml, 0.05 mg / ml, 0.1 mg / ml, 0.2 mg / ml, 0.3 mg / ml, 0.4 mg / ml and 0.5 mg / ml. The protein lysate was diluted 40 times.

[0126] (4) Add the standard and the sample to be tested to a 96-well plate and set up 3 replicate wells. Add 200 μl of BCA solution to each well, incubate at 37°C for 30 minutes, and measure the absorbance at 562 nm using an ELISA reader.

[0127] (5) Calculate the concentration of the sample to be tested based on the standard curve, denature the protein after dilution, and store in a -80°C refrigerator.

[0128] 10.3 SDS-PAGE protein gel experiment

[0129] (1) Glue preparation: In this experiment, the PAGE gel rapid preparation kit with a concentration of 10% was used to prepare the gel. First, prepare the lower layer of gel and add it to the glass plate. Then, press the gel with anhydrous ethanol. After solidification, pour out the anhydrous ethanol, prepare the upper layer of gel according to the instructions, add it to the glass plate, and immediately insert the comb vertically to wait for solidification.

[0130] (2) Sample loading: After the sample is taken out, it is heated at 100°C for 10 minutes and then loaded. Markers are added to the holes on both sides of the protein sample.

[0131] (3) Electrophoresis: First, run at 80 V for 20 minutes, then at 120 V for 70 minutes, until the bromophenol blue reaches the bottom of the glass plate.

[0132] (4) Electroporation: This experiment used semi-dry electroporation to transfer the mold.

[0133] (5) Blocking: Use 5% skimmed milk powder and incubate on a shaker at room temperature for 2 hours.

[0134] (6) Primary antibody incubation: Cut the PVDF membrane and soak it in the primary antibody. Incubate it on a shaker at 4°C overnight.

[0135] (7) Secondary antibody incubation: Soak the PVDF membrane in the secondary antibody solution and incubate at room temperature for 2 hours.

[0136] (8) Luminescence development: development, data preservation.

[0137] (9) Result analysis: Image J software was used for analysis.

[0138] 11. Stereotaxic Injection

[0139] The mouse was anesthetized with isoflurane and then placed on a stereotaxic injection apparatus. The hair on the mouse head was removed, disinfected, and the scalp was cut to expose the skull. Bilateral hippocampal injections were performed according to the mouse brain atlas. After drilling, the virus was injected using a microsyringe. The total amount of virus injected was 2 μl. Three minutes after the tip of the syringe reached the target brain area, the virus was injected at a rate of 50 μl / min. After the injection was completed, the needle was stopped for 10 minutes, and then the microsyringe was slowly removed and the skin was sutured.

Claims

1. Application of ACSL4 in the preparation of products for diagnosis and / or treatment of depression.

2. The application according to claim 1, characterized in that: The therapeutic products include ACSL4 inhibitors to inhibit the expression of ACSL4 gene or ACSL4 protein.

3. The application according to claim 2, characterized in that: The ACSL4 inhibitor improves neuronal morphology and function.

4. The application according to claim 2, characterized in that: The ACSL4 inhibitor inhibits the transcriptional activity of the ACSL4 gene by inhibiting the activity of transcription factors, chromatin remodeling, DNA methylation, and activating or inhibiting cell signaling pathways; The ACSL4 inhibitor selectively reduces ACSL4 translation through RNA splicing regulation, RNA stability regulation, RNA interference, and post-translational modification, thereby controlling the expression level of ACSL4 protein.

5. The use according to claim 2, 3 or 4, characterized in that: The ACSL4 inhibitor is a viral vector that inhibits the expression of ACSL4.

6. The application according to claim 5, characterized in that: The viral vector is an adeno-associated viral vector.

7. The use according to claim 6, characterized in that: The adeno-associated virus vector is an AAV8, AAV1, AAV2, AAV5, AAV6, AAV7, or AAV9 virus vector.

8. The use according to claim 1, characterized in that: The diagnostic supplies include a kit for detecting ACSL4 gene or protein.

9. Use of ACSL4 gene or ACSL4 protein as a target for diagnosis and / or treatment of depression.

10. Use of ACSL4 gene or ACSL4 protein as a drug target for preparing drugs for treating depression.